Nafld Associated With Fluoxetine with Its Probable Management: A Review
DOI:
https://doi.org/10.67499/biospecia.v2i2.221Keywords:
Non-alcoholic fatty liver disease, Fluoxetine, Drug induced liver injury, Inflammation and oxidative stressAbstract
Non-alcoholic fatty liver disease is a major global health related linked to severe metabolic abnormalities. However, effective pharmacological therapies remain restricted. Based on a recent meta-analysis, NAFLD affects 32% of the adult population worldwide. The global incidence of NAFLD is estimated to be 47 cases per 1,000 peoplewhich is greater among males (40%) than females (26%). Drug induced liver injury is commonly caused by Amoxicillin-clavulanate,Azithromycin, Acetaminophen, Methotrexate, Atorvastatin, Ticlopidine and fluoxetine. Selective serotonin receptor inhibitor(fluoxetine)after prolonged therapy shown Non-Alcoholic fatty liver disease (NAFLD).This study focused on evaluation of various natural products for their therapeutic potential.The results suggested that natural compounds displayed promising hepatoprotective benefits, potentially reducing liver damage and increasing liver function through various pathways such as oxidative stress, mitochondrial dysfunction and inflammation. Further research in this area could lead to beneficial preventive and therapeutic strategies for patients suffering from NAFLD due to fluoxetine.
Downloads
References
Hosack, Tom, Djamil Damry, and Sujata Biswas. Drug-induced liver injury: a comprehensive review. Therapeutic Advances in Gastroenterology 16 (2023): 17562848231163410.
Gu, Shaopeng, Govarthanan Rajendiran, Kennedy Forest, Tam C. Tran, Joshua C. Denny, Eric A. Larson, and Russell A. Wilke. Drug‐induced liver injury with commonly used antibiotics in the All of Us Research Program. Clinical Pharmacology & Therapeutics 114, no. 2 (2023): 404-412.
Allison, Rebecca, Asha Guraka, Isaac Thom Shawa, Gyan Tripathi, Wolfgang Moritz, and Ali Kermanizadeh. Drug induced liver injury–a 2023 update. Journal of Toxicology and Environmental Health, Part B 26, no. 8 (2023): 442-467.
Tajiri, Kazuto, and Yukihiro Shimizu. Practical guidelines for diagnosis and early management of drug-induced liver injury.World journal of gastroenterology: WJG 14, no. 44 (2008): 6774.
Ayyash, Ahmed, and Alison C. Holloway. Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ12,14PGJ2. Journal of Applied Toxicology 42, No. 6 (2022): 1004–10152.
Wong, David T., Kenneth W. Perry, and Frank P. Bymaster. The discovery of fluoxetine hydrochloride (Prozac). Nature reviews Drug discovery 4, no. 9 (2005): 764-774.
Liao, Dehua, ChuanfengLv, Lizhi Cao, Dunwu Yao, Yi Wu, Minghui Long, Ni Liu, and Pei Jiang. Curcumin attenuates chronic unpredictable mild stress‐induced depressive‐like behaviors via restoring changes in oxidative stress and the activation of Nrf2 signaling pathway in rats.Oxidative medicine and cellular longevity 2020, no. 1 (2020): 9268083.
Qiao, Yajun, Jiubo Zhao, Cen Li, Ming Zhang, Lixin Wei, Xiaoyuan Zhang, Olga Kurskaya, Hongtao Bi, and Tingting Gao. Effect of combined chronic predictable and unpredictable stress on depression-like symptoms in mice. Annals of translational medicine 8, no. 15 (2020).
Gram, Lars F. Fluoxetine. New England Journal of Medicine 331, no. 20 (1994): 1354-1361.
Ganguly, Risha, Ramesh Kumar, and Abhay K. Pandey. Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation. World Journal of Hepatology 14, No. 4 (2022): 729–743.
Wong, David T., Kenneth W. Perry, and Frank P. Bymaster. The discovery of fluoxetine hydrochloride (Prozac). Nature reviews Drug discovery 4, no. 9 (2005): 764-774.
Rossi, Andrea, Alessandra Barraco, and Pietro Donda. Fluoxetine: a review on evidence based medicine. Annals of general hospital psychiatry.
Gangopadhyay, Anwesha, Radwa Ibrahim, Karli Theberge, Meghan May, and Karen L. Houseknecht. Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines. Frontiers in Neuroscience 16, (2022): 1–16.
Burns, Corrinne. Antidepressant prescribing increases by 35% in six years. Pharmaceutical Journal 309, No. 7963 (2022): 1–4.
Riazi, Kiarash, Hassan Azhari, Jacob H. Charette, Fox E. Underwood, James A. King, Elnaz Ehteshami Afshar, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, and Abdel-Aziz Shaheen. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The lancet gastroenterology & hepatology 7, no. 9 (2022): 851-861.
Puri, Puneet, and Arun J. Sanyal. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. Clinical Liver Disease 1, no. 4 (2012): 99-103.
Wong, Vincent Wai-Sun, Mattias Ekstedt, Grace Lai-Hung Wong, and Hannes Hagström. Changing epidemiology, global trends and implications for outcomes of NAFLD. Journal of hepatology (2023).
Teng, Margaret LP, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, and Mark D. Muthiah. Global incidence and prevalence of non-alcoholic fatty liver disease. Clinical and molecular hepatology 29, no. Supplement (2023): S32.
Chen, Liya, Anna L. Lang, Gavin D. Poff, Wen-Xing Ding, and Juliane I. Beier. Vinyl chloride-induced interaction of nonalcoholic and toxicant-associated steatohepatitis: Protection by the ALDH2 activator Alda-1. Redox biology 24 (2019): 101205.
Karkucinska‐Wieckowska, Agnieszka, Ines CM Simoes, Piotr Kalinowski, Magdalena Lebiedzinska‐ Arciszewska, Krzysztof Zieniewicz, Piotr Milkiewicz, Magdalena Górska‐Ponikowska et al. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. European journal of clinical investigation 52, no. 3 (2022): 13622.
Elgebaly, Hassan A., Nermeen M. Mosa, Mariam Allach, Khaled F. El-massry, Ahmed H. El-Ghorab, Amir M. Al Hroob, and Ayman M. Mahmoud. Olive oil and leaf extract prevent fluoxetine-induced hepatotoxicity by attenuating oxidative stress, inflammation and apoptosis. Biomedicine and Pharmacotherapy 98, (2018): 446–453.
Yilmaz, Ahmet, Bilal Elbey, Ümit Can Yazgan, Ahmet Dönder, Necmi Arslan, Serkan Arslan, Ulaş Alabalik, and Hamza Aslanhan. "Protective effects of caffeic acid phenethyl ester on fluoxetine-induced hepatotoxicity: An experimental study." BioMed Research International 2016, (2016): 1–6.
Ganguly, Risha, Ramesh Kumar, and Abhay K. Pandey. Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation. World Journal of Hepatology 14, No. 4 (2022): 729–743.
Chen, Ze, Ruifeng Tian, Zhigang She, Jingjing Cai, and Hongliang Li. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radical Biology and Medicine 152 (2020): 116-141.
Xu Ping, Xu Ping, Zhang XingGuo Zhang XingGuo, Li YouMing Li YouMing, Yu ChaoHui Yu ChaoHui, Xu Lei Xu Lei, and Xu GenYun Xu GenYun. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. (2006): 627-633.
Davaatseren, Munkhtugs, Haeng Jeon Hur, Hye Jeong Yang, Jin-Taek Hwang, Jae Ho Park, Hyun-Jin Kim, Myung-Sunny Kim, Min Jung Kim, Dae Young Kwon, and Mi Jeong Sung. Dandelion leaf extract protects against liver injury induced by methionine-and choline-deficient diet in mice. Journal of medicinal food 16, no. 1 (2013): 26-33.
Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMCMed2011;9:85.
Mun, Jeongeun, Shintae Kim, Ho-Geun Yoon, Yanghee You, Ok-Kyung Kim, Kyung-Chul Choi, Yoo-Hyun Lee, Jeongmin Lee, Jeongjin Park, and Woojin Jun. Water extract of Curcuma longa L. ameliorates non-alcoholic fatty liver disease. Nutrients 11, no. 10 (2019): 2536.
Ren, Tingting, Juanjuan Zhu, Lili Zhu, and Mingliang Cheng. The combination of blueberry juice and probiotics ameliorate non-alcoholic steatohepatitis (NASH) by affecting SREBP-1c/PNPLA-3 pathway via PPAR-α. Nutrients 9, no. 3 (2017): 198.
Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV. Vitamin D deficiency in obese rats exacerbates non-alcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012; 55: 1103–11.
Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMCMed2011;9:85.
Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients withnon-alcoholic fatty liver disease. NutrMetab Cardiovasc Dis 2007; 17: 517–24.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–23.
Flanagan JL, Simmons PA, VehigeJ, Willcox MD, Garrett Q. Role of carnitine in disease. NutrMetab (Lond). 2010; 7: 30.
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-carnitine supplementation to diet: a new tool in treatment of non-alcoholic steatohepatitis– a randomized and controlled clinical trial. Am J Gastroenterol 2010; 105: 1338–45.
Jump DB, Botolin D, Wang Y, XuJ, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135: 2503–6.
Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M. Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009; 50: 1102–11.
Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R&D 2015; 15: 21.
Feng B, Meng R, Huang B, Shen S, Bi Y, Zhu D. Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice. Free Radic Res 2016; 50: 314–27.
Poulsen M, Vestergaard P F, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Moller N, Jessen N, Pedersen SB, Jorgensen JO. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62: 1186–95.
Salomone, Federico, Justyna Godos, and Shira Zelber‐Sagi. Natural antioxidants for non‐alcoholic fatty liver disease: molecular targets and clinical perspectives." Liver International 36, no. 1 (2016): 5-20.
Dong, Xi, Shan Lu, Yu Tian, Han Ma, Yang Wang, Xuelian Zhang, Guibo Sun, Yun Luo, and Xiaobo Sun. Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA. Journal of Advanced Research 55 (2024): 131-144.
Published
How to Cite
Issue
Section
Citations
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
(CC BY-NC)
.